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Background: Amoxycillin/clavulanate is considered ﬁ  rst-line treatment for ambulatory 
exacerbations of COPD. However, narrow-spectrum antibiotics may be as useful for mild to 
moderate patients.
Objective: To compare the clinical efﬁ  cacy of amoxycillin versus amoxicyllin/clavulanate in 
exacerbations of COPD in primary care.
Methods: A randomized, double-blind, noninferiority clinical trial was carried out in eight 
primary care centers in Catalonia, Spain. Spirometrically-diagnosed patients older than 40 years 
with COPD, without criteria of hospitalization and Anthonisen’s types I or II exacerbations were 
included. The main outcome was clinical cure at the end of treatment (EOT) visit on day 10.
Results: A total of 137 patients were enrolled in the study (68 assigned to amoxycillin and 
69 to amoxycillin/clavulanate). The mean forced expiratory ﬂ  ow in one second was 61.6% 
and the mean age was 71.4 years. At EOT, 92.8% of patients in the amoxycillin/clavulanate and 
90.9% in the amoxycillin group were considered clinically cured, a statistically non-signiﬁ  cant 
difference. Adverse effects were observed in 11 subjects, 3 in the amoxycillin group and 8 in 
the amoxycillin/clavulanate group, 2 of whom required a change in treatment.
Conclusions: Amoxycillin was at least as effective clinically and as safe as amoxycilin/
clavulanate in the treatment of acute exacerbations of COPD in mild to moderate patients in 
primary care.
Keywords: exacerbation, chronic obstructive pulmonary disease, randomised controlled trial, 
amoxycillin, primary care, amoxycillin/clavulanate
Introduction
Chronic obstructive pulmonary disease (COPD) constitutes one of the principal 
demands of medical attention in primary care. According to local studies, it is estimated 
that up to 8%–10% of the population over 40 years of age may be affected by COPD 
and, in men over 65 years of age, this ﬁ  gure may rise to 20%.1 Exacerbations are acute 
episodes of an increase in respiratory symptoms that characterize the course of COPD 
and result in impaired quality of life,2,3 particularly in moderate patients in primary 
care.4 Furthermore, they accelerate the decline in lung function,5 increase health care 
utilization6 and constitute the main cause of death of patients with COPD.7
Although the etiology of COPD exacerbations is not completely established, there 
is strong evidence that potentially pathogenic microorganisms (PPMs) are isolated 
in more than half of COPD patients during exacerbations.8 Another 30%–40% of 
the exacerbations of COPD have recently been shown to be attributable to viruses9,10 
alone or in combination with bacteria.11 The PPMs most commonly isolated during 
exacerbations are aerobic bacteria, with Haemophilus inﬂ  uenzae being the most 
frequent, followed by Streptococcus pneumoniae in second place and Moraxella 
catarrhalis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Pseudomonas International Journal of COPD 2009:4 46
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aeruginosa,12 especially in more severe patients.13 Bacterial 
etiology should be suspected when two or more of the fol-
lowing criteria are present: sputum purulence, increase in 
breathlessness and increase in expectoration volume.14
A recent meta-analysis has shown a reduction in the risk 
of therapeutic failure and death in patients receiving an anti-
biotic compared with those receiving placebo.15 The aims of 
antibiotic therapy in bacterial exacerbations of COPD are: 
a) to reduce the rate of relapse; b) to avoid the worsening of 
pulmonary function and shorten the duration of the exacerba-
tion; and c) to prolong the period between exacerbations.16 
Another recent meta-analysis has demonstrated the superiority 
of the so-called second-line over the oldest, ﬁ  rst-line antibiot-
ics in reducing the rate of relapse.17 However, when deciding 
the antibiotic treatment for exacerbations it is also important 
to consider the resistance patterns of PPMs to the most com-
monly used antibiotics. H. inﬂ  uenzae has become resistant 
because of the production of β-lactamases. Indeed, approxi-
mately 20% of the strains of H. inﬂ  uenzae currently isolated 
in Spain are β-lactamase-producers.18 The prevalence of 
pneumococcal resistance to penicillins is approximately 20%, 
while resistance to amoxycillin or amoxycillin/clavulanate has 
only been detected in less than 5% of isolates in Spain.18 In 
recent years, reduced spectrum penicillins have been replaced 
by broader spectrum penicillins in many countries.19 Indeed, 
the current guidelines for clinical practice recommend the use 
of amoxycillin/clavulanate in patients with acute exacerba-
tions of mild to moderate COPD (500-875/125-mg three times 
daily for 7–10 days), since it covers the most frequent patho-
gens, mainly Haemophilus.20,21 Nonetheless, the administra-
tion of amoxycillin alone could be a valid alternative based 
on resistance proﬁ  les of PPMs isolated in primary care.22 The 
aim of this study was to compare the efﬁ  cacy and tolerability 
of amoxycillin versus amoxycillin/clavulanate in patients with 
ambulatory exacerbations of COPD in primary care.
Method
Population
A randomized, double-blind, parallel group, clinical trial 
was undertaken during ﬁ  ve winter periods from October to 
March, 2000 to 2005 at 8 primary care centers in Catalonia, 
Spain. Patients over 40 years of age were included in the 
study providing they had a spirometric diagnosis of COPD, 
ie, forced expiratory volume in one second (FEV1) 80% 
predicted and post-bronchodilator FEV1/forced vital capacity 
(FVC) ratio 0.7% from a spirometry performed in a stable 
state within 12 months prior to inclusion. An exacerbation 
was deﬁ  ned according to the Anthonisen criteria14 (increased 
dyspnoea, increased sputum volume and purulent sputum), 
and only patients fulﬁ  lling Anthonisen I (all three criteria) 
or II (two criteria present) were enrolled. Patients were 
excluded from the study if they exhibited any of the follow-
ing characteristics: current chronic treatment with systemic 
steroids at any dose, severe respiratory impairment requiring 
hospital referral, evidence of a new pulmonary inﬁ  ltrate on 
chest radiography, suspected or known history of hypersen-
sitivity to β-lactam antibiotics, administration of antibiotics 
within the previous four weeks, documented evidence of 
bronchiectasis, AIDS, another immunosuppressive condi-
tion or patients receiving treatment with immunosuppressive 
drugs, cystic ﬁ  brosis, or patients participating in another 
clinical trial within the last year. The study was approved 
by the Ethics and Research Committee of the Fundació Jordi 
Gol i Gurina (Register 00/03; Barcelona, Spain) institution 
that covers the studies performed in primary care in Catalonia 
(Spain). All the patients were duly informed of the study 
and written informed consent was obtained prior to their 
participation in the trial.
Design of the study
The patients were randomized into two treatment groups: 
amoxycillin (500 mg three times daily for 10 days) or 
amoxycillin/clavulanate (500/125 mg three times daily for 
10 days). The use of antithermic drugs (acetaminophen, 
salicilates or ibuprofen) and oral corticoids up to a maxi-
mum of 30 mg daily during the exacerbation were allowed 
on presentation of fever, pain or breathlessness. Respiratory 
medications for COPD were permitted during the study: 
short-acting and long-acting inhaled β-agonists, anticho-
linergics, theophyllines, inhaled corticoids or any other 
medication, except other antibiotics either as treatment of 
the exacerbation or administered chronically.
Participants were required to take the study medication 
for a minimum of 7 full days, unless there was clear evidence 
of therapeutic failure or the presence of an adverse reaction, 
to be included in the per protocol (PP) population. They were 
requested to return all the unused medication samples to the 
physician to check for compliance. The PP population was 
evaluated for efﬁ  cacy. The intention-to-treat (ITT) population 
consisted of all patients who had taken at least one dosage of 
any of the study medication and was evaluated for safety.
Patients were examined at the time of entry into the 
study (baseline visit) and evaluation of efﬁ  cacy (primary 
outcome) was performed at the end of treatment (EOT visit, 
day 10 ± 1). Clinical efﬁ  cacy was also evaluated at follow-up 
(FU visit, day 30 ± 4).International Journal of COPD 2009:4 47
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A complete medical history was obtained at baseline. 
Demographic variables such as age, sex, smoking status, 
the use of bronchodilator treatment, symptoms and signs, 
Anthonisen’s type of exacerbation, lung function and con-
comitant diseases such as hypertension, hypercholesterol-
emia, diabetes mellitus, coronary heart disease, chronic renal 
failure and heart failure were collected.
We assessed study outcomes on the EOT and FU visits. 
On the EOT visit, clinical response was deﬁ  ned as clinical 
cure (resolution or sufﬁ  cient improvement of the signs and 
symptoms of exacerbation recorded at baseline such that no 
additional antibacterial therapy was prescribed for the epi-
sode of acute exacerbation) or clinical failure (insufﬁ  cient 
reduction in the signs and symptoms of infection requir-
ing the implementation of a new antimicrobial treatment). 
At visit 3, the clinical response was also deﬁ  ned as clinical 
cure (continued resolution or improvement) or failure (non-
response or reappearance of signs and symptoms and need 
for antibacterial therapy). In cases of clinical deterioration, 
the investigator initiated another antibiotic treatment accord-
ing to the clinical criteria. Side effects were evaluated in the 
ITT population and were recorded at all visits and ranked 
by intensity (mild, moderate, severe or serious) and relation-
ship to the study medication. The percentage of patients who 
abandoned treatment due to intolerance and the number of 
relapses and days with recurrence after one month of having 
initiated antibiotic therapy was evaluated.
Statistical analysis
The study was powered as a non-inferiority study, and the 
sample size was calculated in order to demonstrate that 
amoxycillin was not 15% less effective than amoxycillin/
clavulanate. Sample size was based on a predictive cure rate 
of 85% in the amoxycillin/clavulanate group with a 15% 
equivalence between study arms, α: 2.5% (one-sided) and 
β: 20%. Thus, 68 patients were needed per treatment arm, 
including possible losses of 15%. The two treatments groups 
were compared for efﬁ  cacy using the Fisher exact test. For 
comparison of means ± SD of demographic and medical 
characteristics of patients before study entry the Student’s 
t-test was used. For adverse effects a Fisher exact test was 
utilized. Statistical differences were considered signiﬁ  cant 
with a p  0.05.
Results
A total of 173 potential eligible patients were screened 
for inclusion. Of these, 36 were excluded as they did not 
fulﬁ  l the inclusion criteria (29 cases did not have recent 
spirometry), refused to take part in the study or their 
follow-up data were incomplete (Figure 1). One hundred 
thirty-seven patients were eligible for randomization and 
135 (66 patients in the amoxycillin arm and 69 patients in 
the amoxycillin/clavulanate arm) fulﬁ  lled all the criteria for 
the analysis of efﬁ  cacy and formed the PP population. The 
mean age was 71.4 years (SD: 8.5 years). A moderate COPD 
(GOLD stage II; FEV1 between 50% and 80% predicted) was 
observed in 103 patients and a severe COPD (GOLD III; 
FEV1 between 30% and 50% predicted) was found in the 
remaining 32 patients. As shown in Table 1, no statisti-
cally signiﬁ  cant differences were observed between the two 
treatment arms with regard to the main variables analyzed. 
However, patients assigned to the amoxycillin group pre-
sented slightly better pulmonary function than those treated 
with amoxycillin/clavulanate, although the differences were 
not statistically signiﬁ  cant. On the other hand, more patients 
with coronary heart disease were included in the amoxycillin 
group (38.2% and 20.3%, respectively). The mean FEV1 was 
61.6% (SD: 11.5%) and the mean number of exacerbations 
during the previous year was of 1.6 (SD: 1.5). An increase 
in sputum volume (86.9%) and dyspnoea (73.7%) were the 
most relevant clinical data. 62.8% presented an increase in 
the purulence of the sputum. The majority of patients (71.5%) 
had a type II acute exacerbation of COPD.
A total of 133 patients took at least 7 days of antibiotic 
therapy (98.5%). On the EOT visit, 60 patients assigned to 
receive amoxycillin were cured (90.9%) compared to 64 
(92.8%) in the amoxycillin/clavulanate group (Figure 2). 
No statistically signiﬁ  cant differences were found. Treat-
ment failed in nine patients (6 in the amoxycillin group and 
3 in the amoxycillin/clavulanate group) with a change in 
antibiotic being necessary (Table 2). Two additional patients 
assigned to the amoxycillin/clavulanate group presented 
drug-related adverse events and required a different antibac-
terial treatment. These two patients took the medication less 
than seven days. Although the sample size of the study does 
not allow for reliable subgroup statistical analysis, we did 
not ﬁ  nd signiﬁ  cant differences in clinical efﬁ  cacy between 
treatment arms in either patients with type I (amoxycillin/
clavulanate 89.5%, amoxicyllin 85%) or with type II exacer-
bations (amoxycillin/clavulanate 94%, amoxicyllin 93.7%). 
As shown in Table 2, clinical failure was observed in patients 
who presented a lower FEV1, more comorbidities and were 
older than the mean of the group. All failures were cured after 
changing the antibiotic. Adverse events were observed in 
11 subjects, 10 with gastrointestinal symptoms. Eight patients 
(11.6%) receiving amoxycillin/clavulanate experienced International Journal of COPD 2009:4 48
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Potential eligible patients
(n: 173)
No spirometry (n: 29)
Type III exacerbations (n: 3)
Antibiotics taken previously (n: 2)
Participants who fulfilled 
inclusion criteria (n: 139)
Refused to take part
in the study (n: 2)
Patients eligible for
randomization (n: 137)
Amoxycillin Amoxycillin/clavulanate (n: 68) (n: 69)
Lost to follow-up: Lost to follow-up
n: 1 did not return the unused 
n: 0
medication sample
n: 1 did not attend the scheduled 
visit
Analyzed Analyzed
(n: 66) (n: 69)
Figure 1 Trial proﬁ  le ﬂ  ow chart.International Journal of COPD 2009:4 49
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Table 1 Baseline characteristics of the patients participating
Amoxycillin Amoxycillin/
clavulanate
Total
Number of patients 68 69 137
Mean age, years (SD) 71.9 (8.6) 70.8 (8.5) 71.4 (8.5)
Age range, years 53–88 49–85 49–88
Male (%) 53 (77.9) 56 (81.2) 109 (79.6)
Mean FEV1, % (SD) 62.9 (11.0) 60.4 (11.9) 61.6 (11.5)
FEV1 range, % 39–79 32–78 32–79
Smoking status
  Current smoker, n (%) 15 (22.1) 12 (17.4) 27 (19.7)
  Former smoker, n (%) 53 (77.9) 57 (82.6) 110 (80.3)
  Never smoked, n (%) 0 0 0
Number of exacerbations 
in the previous year, n (SD)
1.69 (1.3) 1.56 (1.7) 1.63 (1.5)
Symptoms
 Temperature   38 ºC, n (%) 10 (14.7) 7 (10.1) 17 (12.4)
  Increase in dyspnoea, n (%) 48 (70.6) 53 (76.8) 101 (73.7)
  Increase in sputum volume, n (%) 63 (92.6) 56 (81.2) 119 (86.9)
  Sputum purulence, n (%) 39 (57.4) 47 (68.1) 86 (62.8)
Anthonisen classiﬁ  cation
  I type, n (%) 20 (29.4) 19 (27.5) 39 (28.5)
  II type, n (%) 48 (70.6) 50 (72.5) 98 (71.5)
Comorbidities
  High blood pressure, n (%) 35 (51.5) 38 (55.9) 73 (53.3)*
  Diabetes, n (%) 9 (13.2) 7 (10.1) 16 (11.7)
  Hypercholesterolemia, n (%) 14 (20.6) 18 (26.1) 32 (23.4)
  Coronary heart disease, n (%) [#] 26 (38.2) 14 (20.3) 40 (29.2)
  Heart failure, n (%) 10 (14.7) 4 (5.8) 14 (10.2)
   Uptake of pneumococcal 
vaccine, n (%)
50 (73.5) 49 (71.0) 99 (72.3)
Drugs taken
  Anticholinergics n, (%) 33 (48.5) 35 (50.7) 68 (49.6)
 Long-acting  inhaled  β agonists n, (%) 29 (42.6) 30 (43.5) 59 (43.1)
 Short-acting  inhaled  β agonists n, (%) 61 (89.7) 59 (85.5) 120 (87.6)
  Inhaled glucocorticoids, n (%)[# #] 52 (76.5) 38 (55.1) 90 (65.7)
  Oral glucocorticoids, n (%) 21 (30.9) 19 (27.5) 40 (29.2)
  Theophyllines, n (%) 2 (2.9) 4 (5.8) 6 (4.4)
Abbreviations: FEV1, forced expiratory volume in one second; Anthonisen type I, all three criteria present (increased dyspnoea, increased sputum volume, and purulent 
sputum); Anthonisen type II, only two criteria present.
Notes: #p  0.05; # #p  0.01.
gastrointestinal side effects (2 reports of diarrhea) leading to 
a change in antibiotic in 2 cases. On the other hand, 3 patients 
(4.4%) presented intolerance to amoxycillin (gastrointestinal 
disturbances and itching) although it was not necessary to 
substitute the antimicrobial.
Similar results were observed in both groups on the 
FU visit on day 30. Of the patients cured at day 10, 57 patients 
in the amoxycillin arm (95%) and 62 patients assigned to 
amoxicillin/clavulanate treatment (96.9%) were still con-
sidered to be clinically cured (Figure 2).
Discussion
The results of our study show that treatment with amoxycillin 
is not inferior to amoxycillin/clavulanate regarding clinical International Journal of COPD 2009:4 50
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Figure 2 Clinical cure at days 10 and 30 in the evaluable patients with COPD exacerbation.
Table 2 Failures observed on day 10 after the initiation of antibiotic therapy
Antibiotic Anthonisen 
classiﬁ  cation
Age (yr) FEV1 (%) Comorbid conditions
Amoxycillin Type I 81 43 High blood pressure, heart failure
Amoxycillin Type I 80 65 High blood pressure, coronary heart disease
Amoxycillin Type II 76 45 High blood pressure, coronary heart disease
Amoxycillin Type II 83 65 Hypercholesterolemia, coronary heart disease
Amoxycillin Type II 74 39 None
Amoxycillin Type I 79 44 High blood pressure
Amoxycillin/clavulanate Type I 74 32 High blood pressure, diabetes mellitus, 
hypercholesterolemia, coronary heart failure
Amoxycillin/clavulanate Type II 85 69 None
Amoxycillin/clavulanate Type I 66 51 High blood pressure
Notes: Two patients assigned to amoxycillin/clavulanate discontinued the antibiotic due to adverse effects and were also considered as therapeutic failure.
efﬁ  cacy at 10 and 30 days in patients with types I and II 
ambulatory exacerbations of moderate COPD in primary 
care. Similarly, both drugs were well tolerated, but with a 
higher incidence of gastrointestinal adverse events in the 
group treated with amoxicyllin/clavulanate.
Our study has some limitations. Although we acknowl-
edge the importance of the assessment of bacterial eradication 
in antimicrobial trials, we were not able to investigate the 
bacterial etiology of the exacerbations and the eradication 
rates after antimicrobial treatment. Since the trial was per-
formed in primary care, these microbiological evaluations 
were not readily available in the centers participating in the 
study. This situation reﬂ  ects current clinical practice, in 
which no microbiological analysis of sputum is performed 
in patients with exacerbations of COPD23 and current guide-
lines do not recommend the systematic analysis of sputum International Journal of COPD 2009:4 51
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to direct antimicrobial therapy.20,21 However, the lack of 
microbiological data does not invalidate the conclusions of 
the study. The landmark study on antibiotics in COPD was 
performed based exclusively on clinical efﬁ  cacy,14 as were 
other posterior studies on clinical efﬁ  cacy of antimicrobials 
in this indication.24,25 Furthermore, the diagnostic yield of 
the microbiological analysis of sputum is low, and in most 
clinical trials no more than 30% to 40% of cases have a 
sputum sample with a signiﬁ  cant growth of a PPM, which 
is valid for analysis of microbiological efﬁ  cacy.26–28 Another 
limitation is the lack of statistical power to show the superior-
ity of one antibacterial treatment over the other. Clinicians 
require comparative data of the treatment options available 
to choose the best and safest for each patient.29 However, 
superiority trials require a large sample size that is beyond 
the possibilities of our study. To circumvent this problem, a 
recent meta-analysis has demonstrated the clinical superior-
ity of second-line antibiotics compared with oldest, ﬁ  rst-line 
antibiotics in exacerbations of COPD.17 Nevertheless, this 
meta-analysis did not consider the efﬁ  cacy of individual 
antibiotics compared one by one and the inferior results 
observed with the ﬁ  rst-line antibiotics may not be related 
to all the products in the class. Therefore, we believe that 
showing noninferiority of the most prescribed ﬁ  rst-line 
antibiotic, amoxycillin, compared with one of the most pre-
scribed second-line antibiotic, ie, amoxycillin/clavulanate, 
provides relevant complementary information for practicing 
physicians in primary care.30
On the other hand, our study has several strengths. In 
contrast with other antibiotic trials, our population consisted 
of patients with well characterized COPD diagnosed by spi-
rometry. On many occasions clinical trials do not require this 
condition and diagnosis of chronic bronchitis is enough to 
include patients in the study.26,27,31 The diagnosis of chronic 
bronchitis is very unreliable in primary care32 and this is 
demonstrated by the frequent inclusion of patients who are 
younger than 40 years and a signiﬁ  cant proportion of never 
smokers.26,31 Showing noninferiority between two different 
antibiotics in this population is easy and has a very low 
clinical relevance because the rate of relapse, even without 
antibiotics, is very low.29,33
At day 10 of treatment, 92.8% of patients in the 
amoxycillin/clavulanate group and 90.9% of patients in the 
amoxycillin group were considered clinically cured, a sta-
tistically nonsigniﬁ  cant difference. More side effects were 
observed with amoxycillin/clavulanate even though most 
of these drug-related side effects in both treatment groups 
were mild. Antibiotic-associated diarrhea is a common 
complication of antibiotic treatment and can be triggered 
by any antibiotic but is particularly high with amoxycillin/
clavulanate.34 Clavulanic acid is known to be the cause of this 
adverse effect and the incidence of diarrhoea may be reduced 
when a lower daily dose of clavulanic acid is given.35 In our 
study, only two patients assigned to amoxycillin/clavulanate 
discontinued the antibiotic due to diarrhea. The number of 
changes in antibiotic was similar in the two groups, with 
six cases among those receiving amoxycillin due to clini-
cal failure and ﬁ  ve among those treated with amoxycillin/
clavulanate. In the latter, three were due to therapeutic failure 
and two because of intolerance to the antibiotic. In primary 
care it is important to take the clinical effectiveness of the 
therapeutic regimens into account but it also important to 
know the safety and possible compliance to be achieved 
with the treatment. As is shown in the present survey, the 
greater intolerance found with the use of clavulanic acid did 
not allow correct compliance in all patients.
Evidence related to the efﬁ  cacy of amoxycillin in COPD 
exacerbations is controversial. Georgopoulos and col-
leagues36 compared the efﬁ  cacy and safety of amoxycillin 
at different doses and observed a clinical success rate of 
85.6% using 500 mg three times daily. Mertens and col-
leagues37 found no differences in clinical success between 
amoxycillin and azithromycin. On the other hand, Adams 
and colleagues24 compared the risk of therapeutic failure 
between amoxycillin and other agents such as amoxycillin/
clavulanate, cephalosporins, and quinolones, and observed 
that treatment of the exacerbation with amoxycillin was 
associated with an increased relative risk of failure of 3.37 
compared with the other antimicrobial agents. However, their 
population consisted of more severe patients discharged from 
the emergency room of a Veterans Hospital in the US. It is 
of note that our results cannot be extrapolated to more severe 
COPD patients attended in hospital. Similarly, we cannot 
rule out that amoxycillin/clavulanate could be superior to 
amoxycillin in more severe patients with a higher risk to 
be infected by resistant strains of PPMs. Previous studies 
have suggested that patients with severe airﬂ  ow obstruction 
should receive broad-spectrum antibiotics active against 
P. aeruginosa (ERS, SEPAR). Utilization of aminopenicil-
lins, to which P. aeruginosa and M. catarrhalis are frequently 
resistant, should be avoided in these patients with recurrent 
exacerbations and FEV1 below 35% predicted.13,38,39 An 
increasing number of isolates of beta-lactamase-producing 
strains of H. inﬂ  uenzae has been reported over the last years. 
Nevertheless, in a continuing surveillance study carried out 
in 26 countries, examining the susceptibility of pathogens International Journal of COPD 2009:4 52
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involved in adult community-acquired respiratory tract 
infections, mean beta-lactamase production was observed 
in 16.9% of these strains.40 In a recent study, this percentage 
was even lower in another survey with isolates of twenty 
countries in Europe, eastern Asia and southern Africa.41 Our 
study was carried out in Spain, one of the leading countries 
with a higher production of beta-lactamases, of approxi-
mately 20%. Furthermore, 5% of pneumococcal strains are 
resistant to amoxycillin in our country, compared with most 
countries where the resistance rate to this aminopenicillin 
is uncommonly found. However, a recent work reported 
13% of resistance in South Africa.42 Our study was carried 
out in a country with one of the highest resistance rates and 
therefore the main result highlighting the noninferiority of 
amoxicillin may be extrapolated to other countries with even 
lower rates of resistance.
The therapeutic failures observed in our study presented 
a lower FEV1, more chronic comorbid conditions such as 
hypertension, diabetes or coronary heart disease and were 
older than 66 years. These ﬁ  ndings concur with the risk fac-
tors described for clinical failure24,43–45 and suggest that these 
patients must be closely followed.
Amoxycillin has been the classical antibiotic treatment 
for exacerbations of chronic bronchitis and COPD. However, 
for several years it has been recommended that this drug be 
administered in association with clavulanic acid because of 
the resistance rates of Haemophilus and pneumococci.20,21 
Nonetheless, COPD patients attended by family physicians 
usually have mild or moderate pulmonary disease and are 
often cured with antibiotics with a narrower antibacterial 
spectrum than that recommended in the current guidelines. In 
addition, amoxycillin/clavulanate is more expensive and, as 
other broad-spectrum antibiotics, is associated with a higher 
spread of resistant strains in the community. If the results of 
this study are replicated in other large-scale clinical trials, 
the current recommendations of antimicrobial treatment for 
mild to moderate patients should be reconsidered.
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